The drug Gleevac has been hailed as a life saving treatment for certain types of leukemia. However, just as no two people are alike, no two cancers are exactly alike. For some people, their cancer is resistant to certain treatments.
Good news though… The FDA has recently approved 3 new treatment options for patients with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia that carries the Philadelphia chromosome (Ph+) whose disease is resistant or intolerant to Gleevac.
For these patients, newly approved ponatinib (Iclusig), bosutinib (Bosulif) and omacetaxine (Synribo) offer hope as an effective treatment option. These new drugs work by thwarting treatment-resistant mutations (ponatinib and bosutinib) or by stifling creation of an aberrant protein (omacetaxine).
For more information on these drugs, their contraindications, or assistance in paying for them, check out Chemo101. If you’ve been diagnosed with chronic myeloid leukemia (CML), check out the National CML Society, an incredible, one-stop resource for anything & everything related to CML. Knowledge is power…